Barres was born on September 13, 1954, in West Orange, New Jersey, assigned female. As a child, his salesman father and homemaker mother saw him as a tomboy. Attending a West Orange school, Barres excelled in mathematics and science and was impressed by his eighth-grade teacher, Jeffrey Davis. At the age of 17, he learned that he had been born with Müllerian agenesis. He received surgical correction. He obtained a Bachelor of Science in Biology from Massachusetts Institute of Technology, a medical degree from Dartmouth Medical School, and a residency in neurology at Weill Cornell Medicine. During his residency, Barres noted the lack of knowledge about the causes or cures of neurodegeneration. In studying pathology reports, he noticed a correlation between neural degeneration and irregular patterns of glial cells in the brain and, intrigued, resigned his residency to pursue research in neuroscience at Harvard. He completed a PhD in Neurobiology there in 1990, then did postdoctoral training at University College London under Martin Raff. In 1993, Barres joined the faculty of Neurobiology at the Stanford School of Medicine. After transitioning to male in 1997, Barres published on sexism in the sciences and, in 2008, was appointed to the Chair of Neurobiology at Stanford.
Research
Barres authored or co-authored papers in journals such as NatureNeuroscience, Neuron, Science, and Cell. His research involved study of mammalian glial cells of the central nervous system, including the exploration of their function and development. Much of his early work was published under his previous name, Barbara A. Barres. Some of his earliest work studied vertebrate nervous system development, including how and why many neurons fail to survive shortly after forming connections with their targets. These studies investigated how this programmed cell death, apoptosis, occurred in such a tremendous scale. Additionally, he studied processes such as the prerequisites for and consequences of axon myelination, and the interactions of various signaling molecules such as thyroid-hormone and retinoic acid within the formation of glial cells including oligodendrocytes. Early in his time at Stanford, Barres discovered the importance of glial cells in the formation, development, maturation, and regeneration of neurons. His lab also discovered and developed methods for the purification and culturing of retinal ganglion cells and the glial cells with which they interact, including the oligodendrocytes and astrocytes of the optic nerve. Near the turn of the 21st century he continued his study of glial cells and the mechanisms behind their ability to generate new neurons. He studied control of synapses by glia, and the differentiation of astrocytes by endothelial cells. He investigated the role of the protein Id2 in the control of oligodendrocyte development and established that removing this protein led to premature oligodendrocyte maturation. In the 2010s Barres's research focused on using techniques such as immunopanning, immunohistochemistry, tissue culturing, and patch clamping to: 1) understand the cell-to-cell interactions in the developmental regulation of nodes of Ranvier and myelin sheaths; 2) determine to what extent glial cells play a role in synapse formation and function of synapses; 3) identify the signals that promote retinal ganglia growth and survival, and how such knowledge of these signals could be regenerated post-trauma; 4) identify the functions and developmental mechanisms of gray matter astrocytes. In these objectives, his lab discovered a number of novel glial signals for the induction of myelination, axonal sodium channel clustering, and synapse formation processes. Additionally, his lab characterized these processes and the exact identity of these novel signals.
Experience of sexism
Barres described experiences of gender discrimination at academics in MIT. After solving a difficult math problem that stumped many male students, his professor charged that it was solved for him by a boyfriend. He was the top student in the class, but found it hard to get a willing supervisor for research. He lost a scholarship to a man who had only one publication, while he already had six. While earning a PhD at Harvard, he was told that he was to win a scientific competition, which was evidently between him and one man; the Dean confided to him, “I have read both applications, and it’s going to be you; your application is so much better.” But the award was given to the man, who dropped out of science a year later. After transitioning, he noticed that people who were not aware of his transgender status treated him with respect much more than when he presented as a woman. After delivering his first seminar as a man, one scientist was overheard to comment, “Ben Barres gave a great seminar today, but his work is much better than his sister’s work.” In 2012, he recollected the events of his sex change: Barres was critical of economist Lawrence Summers and others who have claimed that one reason there are fewer women than men in science and engineering professorships might be that fewer women than men had the very high levels of "intrinsic aptitude" that such jobs required. He spoke and wrote openly about being a trans man and his experiences transitioning gender identity in 1997, and his experiences of being treated differently as a female scientist versus a male scientist.
Death
Barres died on December 27, 2017, some 20 months after being diagnosed with pancreatic cancer, at his home in Palo Alto, California. He was survived by two sisters and a brother.
Awards and honors
Barres's research awards include a Life Sciences Research Fellowship, the Klingenstein Fellowship Award, a McKnight Investigator Award, and a Searle Scholar Award. He has also won teaching awards: the Kaiser Award for Excellence in Teaching, and the Kaiser Award for Innovative and Outstanding Contributions to Medical Education. In 2008 he received the Mika SalpeterLifetime Achievement Award. He is inducted member of the Reeve Foundation International Research Consortium on Spinal Cord Injury. He is a co-founder of Annexon Biosciences, Inc., a company making drugs to block neurodegeneration in Alzheimer's and other neurological diseases. He became a member and elected Fellow of the American Association for the Advancement of Science in 2011. In 2013 he was elected to the National Academy of Sciences, becoming the first openly transgender member. Along with biochemist Tom Jessell, he was awarded the Ralph W. Gerard Prize in Neuroscience at the Society for Neuroscience 2016 conference in San Diego.
